Brief: Nanoform Partners With Healthcare Investors To Develop, Commercialise Nanoencorafenib

Nanoform Finland Oyj

20/05/2025 08:01

May 20 (Reuters) - Nanoform Finland Oyj NANOFH.HE

SAID ON MONDAY NANOFORM PARTNERS WITH TWO SPECIALIST HEALTHCARE INVESTORS TO DEVELOP AND COMMERCIALISE NANOENCORAFENIB

SIGNED LETTER OF INTENT TO ESTABLISH BRAFMED LTD, NEW COMPANY TO PROGRESS THE CLINICAL DEVELOPMENT AND OUTLICENSING OF NANOENCORAFENIB

UNDER THE AGREEMENT, BRAFMED LTD WILL PAY NANOFORM SERVICE FEES, LOW SINGLE MILLION DEVELOPMENT MILESTONES, AND UP-TO-MID-SINGLE DIGIT TIERED %-ROYALTY

AT INCORPORATION, BRAFMED LTD IS EXPECTED TO BE A WHOLLY OWNED SUBSIDIARY OF NANOFORM, AND THE INVESTORS PLAN TO INVEST AN INITIAL EUR 2-3 MILLION

OPTION TO INVEST AN ADDITIONAL EUR 1-2 MILLION INTO BRAFMED LTD, AT A PRE-MONEY VALUATION OF EUR 5 MILLION

INVESTMENT IS EXPECTED TO BE SUFFICIENT TO FINANCE THE CLINICAL DEVELOPMENT OF NANOENCORAFENIB UP AND UNTIL ITS COMMERCIALIZATION

 Source text for Workspace: nMFN2Z0YH5
 Further company coverage: NANOFH.HE

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))